From 1990 to 2021, the rate of bipolar disorder has remained relatively stable, with around 0.45 percent of the global population suffering each year. This statistic depicts the percentage of the world population who had bipolar disorder from 1990 to 2021.

Global Mental Health Disorders

Prevalence of Common Mental Health Conditions, 2005-2017

By Amit [source]

About this dataset

This dataset contains valuable information about the prevalence of mental health disorders including schizophrenia, bipolar disorder, eating disorders, anxiety disorders, drug use disorders, depression, and alcohol use disorders from various countries across the globe. Mental health is a critical and complex issue which touches us all and this dataset allows a deeper dive into the quantitative understanding of its prevalence and geographical distribution. With this data at hand one can gain insight on questions such as: which countries have rates of mental illness that are higher or lower than average? Which regions are disproportionately dealing with certain types of mental health disruptions? Who is struggling with particular types of illnesses? This data provides answers to those inquiries as well as helping us gain a better understanding of how we can take action towards increasing global awareness, prevention efforts, and access to vital resources that help individuals become healed and empowered

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides information on the prevalence of mental health disorders globally, with data collected from various countries in a given year. It includes statistics on several types of mental health disorders, such as schizophrenia, bipolar disorder, eating disorders, anxiety disorders, drug use disorders and depression.

Using this dataset can provide useful insights into the prevalence of mental health conditions worldwide. This could be used to better understand how different countries are affected by mental health issues and to identify areas that may need more help or attention. The data is broken down by country or region and year to allow for a better understanding of trends over time.

To use this dataset effectively for research or data analysis purposes it is important to first familiarize yourself with the columns available in the dataset: Entity (country/region), Code (country code), Year (year in which the data was collected), Schizophrenia (%) , Bipolar Disorder (%) , Eating Disorders (%) , Anxiety Disorders (%) , Drug Use Disorders (%) , Depression (%) and Alcohol Use Disorders (%). Each column represents a specific type of mental health disorder and provides information on its prevalence rate in each country/region during that calendar year.

Once you have an understanding of these columns you can begin analyzing the data to gain further insights into global trends related to these mental health conditions. You might perform descriptive analyses such as finding average percentages across different groups (e.g., genders) or time periods, as well as performing inferential analyses like assessing relationships between different variables within your data set (e.g., correlation). Additionally you could create visualizations such as charts, maps or other graphics that help make sense out of large amounts of statistical information easily accessible to a wider audience

Research Ideas

• Creating age-group specific visualizations and infographics that compare the prevalence of mental health disorders in different countries or regions to better understand how the issue of depression or anxiety intersects with factors such as gender, culture, or socioeconomic status.
• Creating a global map visualization that shows the prevalence of different mental health disorders in different countries/regions to demonstrate disparities between places and provide a way for policy makers to better target areas most affected by these issues.
• Developing data visualizations exploring relationships between demographic variables (e.g., gender, age) and prevalence of mental health disorder types such as depression or anxiety disorders in order to gain insight into possible correlations between them

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

See the dataset description for more information.

Columns

File: Mental health Depression disorder Data.csv | Column name | Description | |:------------------------------|:--------------------------------------------------------------------------------------| | Entity | The name of the country or region. (String) | | Code ...

BackgroundBipolar disorder (BD) is a severe mental illness characterized by alternating episodes of mania and depression. Among women of reproductive age (15–49 years), the risk of onset is higher and clinical manifestations are more complex due to the combined influence of hormonal fluctuations, reproductive pressures, and conflicts in social roles. Mental health problems in this population not only significantly impair quality of life but also place a sustained burden on family stability and public health systems. Although awareness of BD has been increasing, studies specifically focusing on the disease burden among women of reproductive age remain limited, particularly lacking systematic analyses based on the latest Global Burden of Disease (GBD) data.MethodsThis study was based on data from the GBD 2021 and systematically analyzed the incidence, prevalence, and disability-adjusted life years (DALYs) of BD among women aged 15–49 at the global, regional, and national levels from 1990 to 2021. We calculated age-standardized incidence rate (ASIR), prevalence rate (ASPR), and DALYs rate (ASDR), along with the estimated annual percentage change (EAPC) for each metric. In addition, cross-national health inequality was assessed using the slope index of inequality (SII) and the concentration index (CII). Future trends in the disease burden were projected to 2041 using a Bayesian age–period–cohort (BAPC) model.ResultsFrom 1990 to 2021, the overall burden of BD among women aged 15–49 years has continued to rise globally. In 2021, the numbers of new cases, prevalent cases, and DALYs were all significantly higher than in 1990. Although the ASIR showed a slight decline (EAPC = −0.07; 95% CI: −0.08 to −0.05), the ASPR and ASDR continued to increase, with EAPC of 0.06 (95% CI: 0.04–0.07) and 0.05 (95% CI: 0.04–0.07), respectively. High-SDI regions ranked highest across all three metrics, while middle-high SDI regions had the lowest ASIR and ASPR, and middle-low SDI regions had the lowest ASDR. Regionally, South Asia bore the heaviest absolute burden in terms of incident cases, prevalence, and DALYs, whereas Oceania had the lightest burden. In terms of standardized rates, Tropical Latin America had the highest ASIR, while Australasia recorded the highest ASPR and ASDR; East Asia had the lowest values across all three indicators. At the national level in 2021, New Zealand reported the highest ASIR, ASPR, and ASDR globally; China had the lowest ASIR, and the Democratic People’s Republic of Korea had the lowest ASPR and ASDR. The burden of BD was positively correlated with the level of socio-demographic development, showing a mild positive correlation between ASIR and SDI, and a stronger correlation for ASPR and ASDR. Age-wise, all age groups saw increases in incident cases, prevalence, and DALYs compared to 1990, with the 35–39 age group showing the greatest rise in incidence, and the 45–49 group the largest increase in prevalence and DALYs. In 2021, the ASIR peaked in the 15–19 age group, while ASPR and ASDR were highest in the 25–29 age group. Health inequality analysis indicated persistent disparities in BD burden between high- and low-SDI countries, with little improvement over the past three decades. Projections using the BAPC model suggest that ASIR, ASPR, and ASDR may slightly decline by 2041, but the overall disease burden is expected to remain high.ConclusionFrom 1990 to 2021, the disease burden of BD among women of reproductive age has continued to rise globally, exhibiting significant regional, national, and socioeconomic disparities. This highlights the uneven development of mental health systems across different settings. Countries should develop more targeted mental health intervention strategies based on their stage of development. It is recommended to strengthen early screening, standardized diagnosis, and long-term comprehensive management for women of reproductive age, in order to effectively reduce the disease burden and improve overall mental health in this population.

Bipolar Disorder Market size was valued at USD 5.56 Billion in 2024 and is projected to reach USD 6.42 Billion by 2032, growing at a CAGR of 2% during the forecast period 2026-2032.

Rising Prevalence of Bipolar Disorder: The alarming rise in diagnosed cases worldwide is a major driver of the bipolar disorder market. Improved diagnostic methods and increased awareness may contribute to this growth, but it also indicates an actual increase in the condition's prevalence. This results in a greater patient population requiring treatment, which drives market growth.

Growing Public Awareness and Reduced Stigma: Historically, mental health issues were stigmatized, limiting people from getting treatment. Fortunately, public awareness campaigns and advocacy activities are reducing this stigma. As more individuals learn about bipolar disorder and acknowledge it as a treatable condition, demand for diagnosis and treatment is expected to rise, propelling market growth.

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was USD 6124.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 3.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 2449.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1837.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1408.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 306.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 122.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
The mood stabilizers category is the fastest growing segment of the Bipolar Disorder Therapeutics Drug industry

Market Dynamics of Bipolar Disorder Therapeutics Drug Market

Key Drivers for Bipolar Disorder Therapeutics Drug Market

Rising Rates of Bipolar Disorder Globally to Boost Market Growth

The Bipolar Disorder Therapeutics Drug industry is growing largely because of an upsurge in the incidence of bipolar disorder. Growing numbers of instances linked to lifestyle, environmental, and genetic factors are driving up the need for efficient therapies. As mental health awareness grows, more people are seeking treatment and diagnosis, which frequently entails long-term medication. Moreover, increased diagnosis rates are a result of early detection techniques and increased acceptance of mental health conditions. In order to properly treat bipolar disorder, a variety of drugs, such as mood stabilizers, antipsychotics, and antidepressants, are in high demand due to this expanding patient base. In response to the rising prevalence, pharmaceutical companies are spending money on research to create novel medications, which will help the market grow. /p>

Increasing Understanding of Mental Health to Drive Market Growth

The bipolar disorder therapeutics drug market is being driven mostly by increased awareness of mental health issues. The prejudice linked to mental illness is being lessened by public and healthcare initiatives, which encourage more people to seek bipolar disorder diagnosis and treatment. Campaigns by governments, prominent public figures, and mental health groups have emphasized the significance of identifying symptoms and seeking professional assistance. Higher diagnosis rates are a result of these changes in societal views, and pharmaceutical therapy is frequently used as a primary treatment component. Additionally, better adherence to medicine due to greater awareness of the importance of long-term management has led to a continued demand for therapies. Because mental health issues are becoming more widely recognized, bipolar illness is now being treated more proactively by both patients and clinicians, which is driving innovation and market expansion.

Restraint Factor for the Bipolar Disorder Therapeutics Drug Market

Side Effects of Medications Such as Weight Gain, Sedation, and Metabolic Issues, Will Limit Market Growth

The market for therapeutic drugs for bipolar disorder is severely constrained by side effects, which cause patients to stop taking their prescriptions as prescribed. Weight gain, sedation, and cognitive impairment are examples of adverse effects that might lower a patient's quality of life and lead to therapy discontinuation. Relapses could occur as a result of this cessation, making disorder management more difficult. Furthermore, mistrust of treatment procedures may be stoked by the perception that drugs are useless because of adverse effects. Treatment may also take longer if frequent drug modifications are required to minimize negative effects. Additionally, medical professionals might be reluctant to recommend specific drugs with known side effects, which would further reduce the range of available treatments and hinder market expansion.

Impact of Covid-19 on the Bipolar Disorder The...

Ultra-Long-Acting Antipsychotic Injectables Market Outlook

According to our latest research, the Ultra-Long-Acting Antipsychotic Injectables market size reached USD 4.82 billion globally in 2024, demonstrating robust growth with a projected compound annual growth rate (CAGR) of 7.6% from 2025 to 2033. By 2033, the market is forecasted to attain a valuation of approximately USD 9.39 billion. This significant expansion is primarily driven by the rising prevalence of chronic mental health disorders, increasing adoption of long-acting formulations to improve patient adherence, and ongoing advancements in drug delivery technologies. As per our comprehensive analysis, the Ultra-Long-Acting Antipsychotic Injectables market is poised for sustained growth, fueled by both clinical demand and innovation in psychiatric care.

One of the most influential growth factors for the Ultra-Long-Acting Antipsychotic Injectables market is the escalating incidence of psychiatric disorders such as schizophrenia and bipolar disorder worldwide. The World Health Organization estimates that over 24 million people globally are affected by schizophrenia, a condition demanding long-term management and consistent medication adherence. Traditional oral antipsychotics often face challenges with patient compliance, leading to frequent relapses and hospitalizations. Ultra-long-acting injectables offer a critical solution by delivering steady medication over extended periods, thus minimizing the risk of missed doses and improving overall treatment outcomes. This clinical advantage is increasingly recognized by mental health professionals, driving higher prescription rates and propelling market growth.

Another key driver is the growing preference for patient-centric treatment models in psychiatric care. Healthcare systems and providers are under mounting pressure to optimize resource utilization and reduce the burden of frequent hospital admissions. Ultra-long-acting antipsychotic injectables align perfectly with these objectives, as they facilitate outpatient management and reduce the need for intensive monitoring. Furthermore, these formulations contribute to enhanced quality of life for patients, offering convenience and reducing the stigma associated with daily medication intake. The cumulative impact of these factors is reflected in the expanding adoption of these drugs across both developed and emerging markets, reinforcing their position as a cornerstone of modern psychiatric pharmacotherapy.

Technological innovation in drug formulation and delivery mechanisms is another catalyst accelerating the Ultra-Long-Acting Antipsychotic Injectables market. Pharmaceutical companies are investing heavily in research and development to extend the dosing intervals, improve the pharmacokinetic profiles, and minimize side effects of these medications. The introduction of novel compounds and the approval of new indications have broadened the therapeutic landscape, enabling more tailored and effective interventions for diverse patient populations. Regulatory agencies are also demonstrating greater receptivity to these advancements, as evidenced by expedited approvals and favorable reimbursement policies in several regions. Collectively, these developments are creating a fertile environment for sustained market expansion.

From a regional perspective, North America continues to dominate the Ultra-Long-Acting Antipsychotic Injectables market, accounting for the largest revenue share in 2024. This leadership is attributed to a well-established healthcare infrastructure, high awareness levels among clinicians and patients, and proactive government initiatives supporting mental health care. Europe follows closely, benefiting from robust reimbursement frameworks and increasing investments in psychiatric research. Meanwhile, the Asia Pacific region is witnessing the fastest growth, driven by rising healthcare expenditures, expanding access to mental health services, and a growing burden of psychiatric disorders. Latin America and the Middle East & Africa, while currently representing smaller shares, are expected to register steady growth as awareness and healthcare access improve.

Snapshot img

Antidepressants Drugs Market Size 2025-2029

The antidepressants drugs market size is valued to increase USD 4.59 billion, at a CAGR of 4.6% from 2024 to 2029. Rising prevalence of depression will drive the antidepressants drugs market.

Major Market Trends & Insights

North America dominated the market and accounted for a 37% growth during the forecast period.
By Disease Type - Major depressive disorder segment was valued at USD 6.62 billion in 2023
By Distribution Channel - Retail pharmacies segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: 41.10 million
Market Future Opportunities: USD 4.59 billion 
CAGR : 4.6%
North America: Largest market in 2023

Market Summary

The market represents a significant and continually evolving sector in the healthcare industry. Core technologies, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), dominate the market, accounting for over 70% of the global antidepressants market share. Applications span various mental health conditions, including major depressive disorder, generalized anxiety disorder, and bipolar disorder. Regulations play a crucial role in shaping the market, with stringent approval processes and increasing focus on safety and efficacy. The forecast period, which extends into the next decade, presents both challenges and opportunities.
The rising prevalence of depression, with approximately 264 million people affected worldwide, fuels market growth. However, the development and approval of new drugs, coupled with the social stigma associated with depression and lack of awareness among people, pose significant challenges. Related markets such as the neurostimulation devices and psychotherapy services offer potential opportunities for collaboration and expansion.

What will be the Size of the Antidepressants Drugs Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Antidepressants Drugs Market Segmented and what are the key trends of market segmentation?

The antidepressants drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Major depressive disorder
  Obsessive compulsive disorder
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Route Of Administration

  Oral
  Intravenous (IV)
  Nasal
  Subcutaneous
  Others


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Greece
    Italy


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Disease Type Insights

The major depressive disorder segment is estimated to witness significant growth during the forecast period.

The antidepressant drugs market encompasses various classes of medications, including norepinephrine reuptake inhibitors and atypical antidepressants. Preclinical studies have shown that these drugs modulate neurochemical pathways, such as monoamine oxidase inhibition and neurotransmitter modulation, to alleviate symptoms of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD). Pharmacokinetics, including drug clearance and antidepressant drug metabolism, play a crucial role in the efficacy of these medications. For instance, serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) have demonstrated significant therapeutic benefits, with a 30% response rate in patients with treatment-resistant depression.

Request Free Sample

The Major depressive disorder segment was valued at USD 6.62 billion in 2019 and showed a gradual increase during the forecast period.

Pharmacogenomics also influences antidepressant efficacy, as genetic predisposition and receptor binding affinity can impact drug response. For example, the half-life of tricyclic antidepressants and tetracyclic antidepressants can vary significantly between individuals, necessitating individualized dosing. The market for antidepressant drugs is anticipated to expand substantially, with an estimated 32% of adults in the United States experiencing an anxiety or mood disorder at some point in their lives. Furthermore, the growing understanding of the molecular mechanisms underlying these disorders and the development of novel therapeutic approaches are expected to fuel market growth. In clinical trials, antidepressants have shown promising results in improving synaptic transmission and second messenger systems, leading to enhanced mood regulation and reduced symptoms of depression and anxi